Rubitecan OverviewRubitecan (INN, marketing name Orathecin) is an oral topoisomerase inhibitor, developed by Supergen (now Astex Pharmaceuticals, Inc.; a member of the Otsuka Group). Contents 1 History 2 Synthesis 3 Use as Anti-Cancer Drug 4 References History On January 27, 2004, Supergen announced that it has completed the submission of an NDA for rubitecan to the US FDA, and was accepted for filing on March 2004. On January 2005, Supergen withdrew the NDA for r...
Read more Rubitecan Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Rubitecan
Recent Rubitecan Forums:Be the first to start a discussion about this drug.
Other drugs which contain Rubitecan or a similar ingredient: (1 result)
- ORATHECIN Rubitecan